MACSF

COMMUNIQUÉS West-GlobeNewswire

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
01/07/2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today [...]
Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance
01/07/2025
Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos’ Patented and FDA-Cleared Oral Appliance Treatment LITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos [...]
PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results and Form 10-K Filing
01/07/2025
DELRAY BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today provided an update on the status of its fourth quarter and FY [...]
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
01/07/2025
New law goes into effect on July 1 st authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE [...]
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
01/07/2025
Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn’s ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal Cancers Congress 2025 [...]
Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio
01/07/2025
Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commenced Thomas Schmidt appointed permanent Chief Financial Officer [...]
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
01/07/2025
SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced [...]
Earth Science Tech, Inc. Qualifies for and Joins New OTCID Tier
01/07/2025
Miami, FL, July 01, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring, optimizing, and scaling high-potential operating businesses [...]
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
01/07/2025
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 2- and 6-week interim safety results [...]
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
01/07/2025
MEDIA RELEASE Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 years Ongoing investment in in-house [...]
H.H.C. Group Celebrates 30 Years of Industry Leadership in Healthcare Cost Containment
01/07/2025
ROCKVILLE, Md., July 01, 2025 (GLOBE NEWSWIRE) -- H.H.C. Group (H.H.C.), a leader in reducing healthcare costs by providing high-quality cost containment using claim negotiation, repricing and independent review [...]
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
01/07/2025
MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it [...]
Aviv Clinics Partners with Koterra to Expand Veteran Access to Lifesaving TBI and PTSD Treatment
01/07/2025
World-renowned brain treatment center is teaming up with a Tampa-based nonprofit to bring hyperbaric oxygen therapy treatments for Veterans across the country THE VILLAGES, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Every [...]
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
01/07/2025
REYKJAVIK, ICELAND and LONDON, UK (July 1, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma [...]
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
01/07/2025
REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and [...]
AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2025
01/07/2025
COMMUNIQUE DE PRESSE RESULTATS DE L’ASSEMBLEE GENERALE MIXTE DU 30 JUIN 2025 Paris, 1 er juillet 2025, 10h15 Les actionnaires de la société AB Science se sont réunis en Assemblée Générale Mixte, le lundi 30 juin 2025 à [...]
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
01/07/2025
Genitourinary Tumor Study Ongoing with Active Screening and Enrollment MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a total of [...]
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
01/07/2025
Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose Both 8 mg and 12 mg single doses of BPL-003 showed statistically [...]
ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
01/07/2025
RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosterone No FDA-approved oral therapies currently exist for this underserved [...]

Pages